Human peripheral blood monocytes display surface antigens recognized by monoclonal antinuclear antibodies.
We used monoclonal anti-nuclear autoantibodies and indirect immunofluorescence to examine normal human peripheral blood mononuclear leukocytes for the presence of cell surface nuclear antigens. Only one monoclonal anti-histone antibody (MH-2) was found to bind to freshly isolated PBL, staining approximately 10% of large cells. However, after cells were placed into culture for 16-24 h, a high percentage (up to 60%) of large-sized cells were recognized by an anti-DNA (BWD-1) and several different antihistone monoclonal antibodies (BWH-1, MH-1, and MH-2). These antibodies recognize separate antigenic determinants on chromatin and histones extracted from chromatin. None of the monoclonal autoantibodies appeared to bind to a significant percentage of cells of relatively small cell size, either before or after culture. The histone antigen-positive cells were viable, and the monoclonal antibodies could be shown to be binding to the cell surface and not to the nucleus. Further experiments, including those using aggregated Ig to block antibody binding, strongly indicated that anti-histone antibody binding was not Fc receptor mediated. Using monoclonal antibodies specific for monocytes and T cells, and complement-mediated cytotoxicity, the cells bearing histone antigens were shown to be primarily monocytes. The appearance of histone and DNA antigen-positive cells was nearly completely inhibited by the addition of low concentrations (0.25 micrograms/ml) of cycloheximide at initiation of the cultures. In contrast, little effect on the percentage of positive cells was detected if cells were exposed to high doses of gamma irradiation before culture. These data further support the existence of cell surface nuclear antigens on selected cell subsets, which may provide insight into the immunopathogenesis of systemic lupus erythematosus and related autoimmune diseases.
D000818:Animals; D000974:Antibodies, Antinuclear / Q000276:immunology*; D000911:Antibodies, Monoclonal / Q000276:immunology*; D000941:Antigens / Q000032:analysis*; D000954:Antigens, Surface / Q000032:analysis* / Q000276:immunology / Q000528:radiation effects; D001324:Autoantigens / Q000032:analysis* / Q000276:immunology / Q000528:radiation effects; D001666:Binding Sites, Antibody; D002478:Cells, Cultured; D003513:Cycloheximide / Q000494:pharmacology; D006657:Histones / Q000037:antagonists & inhibitors / Q000276:immunology / Q000528:radiation effects; D006801:Humans; D007700:Kinetics; D008214:Lymphocytes / Q000378:metabolism / Q000528:radiation effects; D051379:Mice; D009000:Monocytes / Q000276:immunology*; D011961:Receptors, Fc / Q000502:physiology
D000974:Antibodies, Antinuclear; D000911:Antibodies, Monoclonal; D000941:Antigens; D000954:Antigens, Surface; D001324:Autoantigens; D006657:Histones; D011961:Receptors, Fc; D003513:Cycloheximide